FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 842 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR After Misdiagnosis, Mom Found Out She Had Terminal Breast Cancer Shortly... April 3, 2019 Marshall University Study Finds That Walnuts Suppress Breast Cancer Growth And... April 16, 2019 T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast... May 23, 2019 Tesco is making it even easier to support life-saving research February 3, 2023 Load more HOT NEWS ΗΛΕΚΤΡΟΧΗΜΕΙΟΘΕΡΑΠΕΙΑ: Η ΝΕΑ ΠΡΩΤΟΠΟΡΙΑΚΗ ΠΡΟΣΕΓΓΙΣΗ ΓΙΑ ΘΕΡΑΠΕΙΑ ΟΓΚΩΝ 2026 ESMO TAT Honorary Award Recipient Announced Neratinib Plus Capecitabine Outperforms Lapatinib Plus Capecitabine in Asian Patients with... Cancer in My Community: Caring for Children With Cancer in Paraguay
